Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer

Abstract

Deregulation of the BCL-2 family interactions ensures cancer resistance to apoptosis and is a major challenge to current treatments. Here the authors describe a novel therapeutic strategy to overcome two anti-apoptotic mechanisms for cancer therapy.